Agavni Mesropian
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.
Journal: Cell reports. Medicine
Published: July 27, 2025
Molecular insights into early malignant transition of hepatocellular carcinoma.
Journal: Cancer cell
Published: June 15, 2025
Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma.
Journal: JHEP reports : innovation in hepatology
Published: June 06, 2025
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.
Journal: Molecular oncology
Published: May 29, 2025
Molecular insights into early malignant transition of hepatocellular carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: May 05, 2025
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 25, 2025
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.
Journal: JHEP reports : innovation in hepatology
Published: April 05, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
Journal: Journal of hepatology
Published: February 02, 2024
Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling.
Journal: Nature genetics
Published: August 16, 2023
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Journal: Gut
Published: August 24, 2021
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: November 25, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026